High-growth stocks that are financially stable are attractive for many reasons. They provide a strong upside to your portfolio, with less likelihood of downside risks compared to less financially robust companies. If your holdings could benefit from diversification towards growth stocks, whether it be in reputable tech stocks or green small-caps, take a look at my list of stocks with a bright future ahead.

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (SEHK:1558)

YiChang HEC ChangJiang Pharmaceutical Co., Ltd., a pharmaceutical manufacturing company, engages in the development, manufacture, and sale of pharmaceutical products in the therapeutic areas of anti-virus, endocrine, metabolic, cardiovascular, and antineoplastic diseases in the People’s Republic of China. Started in 2001, and now led by CEO Juncai Jiang, the company currently employs 1,997 people and has a market cap of HKD HK$8.63B, putting it in the mid-cap stocks category.

An outstanding 17.23% earnings growth is forecasted for 1558, driven by an underlying sales growth of 31.07% over the next few years. Profit growth, coupled with top-line expansion, is a positive indication. This is because net income isn’t artificially inflated by unsustainable activities such as one-off cost-reductions expected in the future. This prospective profitability should trickle down to shareholders, with analysts expecting the company to generate a high double-digit return on equity of 20.85%. 1558’s bullish prospects on both the top and bottom lines make it an interesting stock to invest more time to understand how it can add value to your portfolio. Want to know more about 1558? Other fundamental factors you should also consider can be found here.

China Resources Land Limited (SEHK:1109)

China Resources Land Limited, an investment holding company, develops, invests in, manages, and sells properties in the People’s Republic of China. The company employs 38087 people and with the stock’s market cap sitting at HKD HK$200.59B, it comes under the large-cap stocks category.

1109 is expected to deliver a buoyant earnings growth over the next couple of years of 14.17%, bolstered by an equally impressive revenue growth of 53.25%. Profit growth, coupled with top-line expansion, is a positive indication. This is because net income isn’t artificially inflated by unsustainable activities such as one-off cost-reductions expected in the future. This prospective profitability should trickle down to shareholders, with analysts expecting the company to generate a positive return on equity of 17.44%. 1109 ticks the boxes for high-growth generation on all levels of line items, which makes it an appealing stock to dig into deeper. A potential addition to your portfolio? I recommend researching its fundamentals here.